Back

Ancestry and somatic profile predict acral melanoma origin and prognosis

Basurto-Lozada, P.; Vazquez-Cruz, M. E.; Molina-Aguilar, C.; Jiang, A.; Deacon, D. C.; Cerrato-Izaguirre, D.; Simonin-Wilmer, I.; Arriaga-Gonzalez, F. G.; Contreras-Ramirez, K. L.; Dawson, E. T.; Wong-Ramirez, J. R. C.; Ramos-Galguera, J. I.; Alvarez-Cano, A.; Garcia-Ortega, D. Y.; Garcia-Salinas, O. I.; Hidalgo-Miranda, A.; Cisneros-Villanueva, M.; Martinez-Said, H.; Arends, M. J.; Ferreira, I.; Tullett, M.; Olvera-Leon, R.; van der Weyden, L.; Del Castillo Velasco-Herrera, M.; Roldan-Marin, R.; Vidaurri de la Cruz, H.; Tavares-de-la-Paz, L. A.; Hinojosa-Ugarte, D.; Belote, R. L.; Bishop, D.

2024-09-24 genetic and genomic medicine
10.1101/2024.09.21.24313911 medRxiv
Show abstract

Acral melanoma, which is not ultraviolet (UV)-associated, is the most common type of melanoma in several low- and middle-income countries including Mexico. Latin American samples are significantly underrepresented in global cancer genomics studies, which directly affects patients in these regions as it is known that cancer risk and incidence may be influenced by ancestry and environmental exposures. To address this, we characterise the genome and transcriptome of 123 acral melanoma tumours from 92 Mexican patients, a population notable because of its genetic admixture. Compared with other studies of melanoma, we found fewer frequent mutations in classical driver genes such as BRAF, NRAS or NF1. While most patients had predominantly Amerindian genetic ancestry, those with higher European ancestry had increased frequency of BRAF mutations and a lower median number of structural variants. The tumours with activating BRAF mutations have a transcriptional profile more similar to cutaneous non-volar melanocytes, suggesting that acral melanomas in these patients may arise from a distinct cell of origin compared to other tumours arising in these locations. KIT mutations were found in a subset of these tumours, and quadruple wild-type samples (non BRAF/NRAS/NF1/KIT) differed from mutated samples in their structural genomic profile and overall and recurrence-free survival patterns. Transcriptional profiling defined three expression clusters; these characteristics were associated with recurrence-free and overall survival. We highlight potential novel low-frequency drivers, such as PTPRJ, NF2 and RDH5. Our study enhances knowledge of this understudied disease and underscores the importance of including samples from diverse ancestries in cancer genomics studies.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Pigment Cell & Melanoma Research
11 papers in training set
Top 0.1%
28.5%
2
Nature Communications
4913 papers in training set
Top 16%
10.8%
3
Cancers
200 papers in training set
Top 0.5%
8.7%
4
Journal of Investigative Dermatology
42 papers in training set
Top 0.1%
5.0%
50% of probability mass above
5
Scientific Reports
3102 papers in training set
Top 30%
4.1%
6
Frontiers in Genetics
197 papers in training set
Top 2%
3.3%
7
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.1%
3.2%
8
Genome Medicine
154 papers in training set
Top 3%
2.2%
9
The American Journal of Human Genetics
206 papers in training set
Top 2%
1.9%
10
European Journal of Human Genetics
49 papers in training set
Top 0.5%
1.8%
11
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.3%
1.7%
12
Cell Genomics
162 papers in training set
Top 3%
1.7%
13
eLife
5422 papers in training set
Top 41%
1.7%
14
Annals of Oncology
13 papers in training set
Top 0.5%
1.5%
15
European Journal of Cancer
10 papers in training set
Top 0.3%
1.3%
16
Human Genomics
21 papers in training set
Top 0.2%
1.0%
17
Frontiers in Oncology
95 papers in training set
Top 3%
0.9%
18
PLOS ONE
4510 papers in training set
Top 65%
0.8%
19
Journal of Medical Genetics
28 papers in training set
Top 0.5%
0.8%
20
Journal of Translational Medicine
46 papers in training set
Top 2%
0.8%
21
iScience
1063 papers in training set
Top 33%
0.7%
22
Genes
126 papers in training set
Top 4%
0.7%
23
Cancer Research
116 papers in training set
Top 4%
0.7%
24
Genomics
60 papers in training set
Top 3%
0.7%
25
Frontiers in Immunology
586 papers in training set
Top 9%
0.5%
26
PLOS Genetics
756 papers in training set
Top 18%
0.5%
27
Molecular Oncology
50 papers in training set
Top 1%
0.5%